1. Home
  2. FSBW vs TSHA Comparison

FSBW vs TSHA Comparison

Compare FSBW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FS Bancorp Inc.

FSBW

FS Bancorp Inc.

HOLD

Current Price

$44.15

Market Cap

332.6M

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.02

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSBW
TSHA
Founded
1936
2019
Country
United States
United States
Employees
537
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
332.6M
1.7B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
FSBW
TSHA
Price
$44.15
$5.02
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$46.00
$11.63
AVG Volume (30 Days)
17.2K
2.0M
Earning Date
04-21-2026
05-06-2026
Dividend Yield
2.79%
N/A
EPS Growth
N/A
5.56
EPS
2.07
N/A
Revenue
$4,612,000.00
$9,773,000.00
Revenue This Year
$14.94
N/A
Revenue Next Year
$10.47
$1,152.42
P/E Ratio
$21.42
N/A
Revenue Growth
44.80
17.28
52 Week Low
$36.85
$2.72
52 Week High
$45.85
$7.30

Technical Indicators

Market Signals
Indicator
FSBW
TSHA
Relative Strength Index (RSI) 57.64 33.36
Support Level $41.09 $4.37
Resistance Level $44.89 $5.07
Average True Range (ATR) 0.73 0.25
MACD 0.14 -0.04
Stochastic Oscillator 67.77 10.85

Price Performance

Historical Comparison
FSBW
TSHA

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: